Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Monday. The firm issued a hold rating on the stock.

A number of other brokerages have also issued reports on EKSO. Lake Street Capital started coverage on Ekso Bionics in a research report on Monday, June 24th. They set a buy rating and a $2.50 target price on the stock. HC Wainwright reaffirmed a buy rating and set a $10.00 target price on shares of Ekso Bionics in a research report on Tuesday, July 30th.

Ekso Bionics Stock Performance

Shares of EKSO stock opened at $1.23 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.77 and a current ratio of 2.42. Ekso Bionics has a 1 year low of $0.62 and a 1 year high of $3.13. The stock has a fifty day moving average of $1.12 and a two-hundred day moving average of $1.23. The firm has a market capitalization of $22.68 million, a PE ratio of -1.27 and a beta of 1.45.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The business had revenue of $4.95 million for the quarter, compared to analyst estimates of $5.34 million. During the same quarter last year, the firm posted ($0.31) EPS. As a group, research analysts expect that Ekso Bionics will post -0.42 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC raised its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. 6.42% of the stock is owned by institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.